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Abstract : 
We report two cases of non-smoker patients diagnosed with EGFR-mutated lung 
adenocarcinoma and bearing germinal TP53 gene mutation, also known as Li-Fraumeni 
syndrome (LFS). We describe for the first time an EGFR-TKI resistance mutation in this 
population. Finally, we provide an analysis of discerning epidemiological data obtained from 
the IARC database and from all the published cases of EGFR-mutated lung cancer in TP53
germline mutation carriers. 
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Introduction 
Li-Fraumeni syndrome (LFS) was initially described in the late 60’s, based on the report of 
four families with high tumor occurrence [1]. This condition has been characterized by an 
autosomal dominant predisposition to various malignancies. The principal localizations are 
sarcomas, gliomas and breast carcinomas. Direct involvement of germline TP53 gene 
mutations has emerged approximately two decades after the primary description [2]. In most 
cases, mutation of the TP53 tumor suppressor gene result in a loss-of-function of p53 protein, 
leading to alterations in DNA repair, apoptosis cell-cycle control and consequently genome 
instability [3]. A worldwide database is now collecting both somatic and germline TP53
mutation on International Agency for Research on Cancer (p53.iarc.fr). Despite growing 
knowledge about LFS, prevalence of lung cancer is still unknown in this population but an 
increased risk has been described in observational studies [4]. Moreover, the literature is still 
scarce regarding the molecular abnormalities of lung neoplasms in this particular setting. An 
early report suggests an association between tumoral TP53 mutation and EGFR-driven lung 
cancer [5].  
We report two cases of patients with LFS and EGFR-mutated lung adenocarcinoma, and 
provide the first description of resistance mutation to EGFR-TKI in this population. We 
highlight a potentially underreported association and emphasize the need for molecular 
alterations compiling in the particular setting of LFS. Reviewing all the published cases to 
date, we finally bring perspectives for clinical management. 
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Cases
 A fifty-five year old non-smoker man was diagnosed with a lower left leg deep venous 
thrombosis in December 2010. CT-scan evaluation revealed upper right lobe lung mass, 
abnormal mediastinal lymph nodes and two liver lesions. A liver biopsy confirmed the 
presence of a metastatic localization of a stage IV (T2a N3 M1b) lung adenocarcinoma. 
Eastern cooperative oncology group (ECOG) performance status was quantified to 0 at 
diagnosis. The patient was known to carry a LFS, because emergence of unusual childhood 
tumors in descendants led to germline TP53 gene sequencing a few years ago (TP53 germline 
mutation H179Y). First line chemotherapy with platinum and pemetrexed was administered, 
followed by EGFR-TKI (erlotinib). Three months later, paclitaxel was prescribed because of a 
cervical and mediastinal progression, which stabilized the disease for eight months. 
Symptomatic pleural effusion occurred and the patient clinically benefit from a re-challenge 
of platinum doublet chemotherapy. Approximately two years after diagnosis, CT-scan guided 
biopsy was performed on a new pulmonary nodule to assess tumoral molecular abnormality 
status and rule out transition to small cell lung cancer. The presence of an adenocarcinoma 
with both an EGFR exon 19 deletion (del2235–2249, delE745-A750) and an exon 20 T790M 
(c.2369C>T) mutation was confirmed respectively by automated electrophoresis system 
(LabChip GX) and pyrosequencing (figure 1, panel A and B). A tumoral TP53 gene mutation 
was also found, similarly to the germline mutation previously described (data not shown). No 
mutation on HER2, PI3KCA, BRAF or KRAS genes or rearrangement of ALK gene was 
found. A fourth line of chemotherapy was proposed with an objective response observed after 
4 cycles of carboplatin pemetrexed bevacizumab. The patient died a few months later from 
rapidly progressive pulmonary lymphangitic carcinomatosis (figure 1, panel C). 
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 A fifty-seven year old woman presented with a two month history of inflammatory lumbar 
pain in November 2008. MRI evaluation revealed a body lesion of L1 suspect of malignant 
origin. Needle bone biopsy confirmed the presence of a secondary metastasis of an upper left 
lobe lung adenocarcinoma. It was a stage IV (T2aN2M1b) disease and ECOG performance 
status was quantified to 0 at diagnosis.  She never smoked and presented right breast 
carcinoma in 2002, treated by surgery and radiation. EGFR status was unknown at diagnosis 
because bone sample conditioning does not allow us to perform molecular analysis. After two 
cycles of cisplatin vinorelbin, the disease progressed, therefore erlotinib was prescribed. This 
therapy resulted in a significant and prolonged response. In october 2009, she was tested for 
germline TP53 mutation because her daughter was diagnosed with corticosurrenaloma. LFS 
was confirmed (TP53 mutation R273H). Thoracic progression occurred in November 2011 
and the patient was enrolled in a phase 1 study evaluating an irreversible EGFR-TKI inhibitor 
(afatinib). Pleural metastasis was diagnosed in March 2012 and the targeted therapy was 
stopped. A surgical pleurodesis showed pleural localization of an adenocarcinoma with EGFR
exon 21 mutation L858R (c.2573T>G) without T790M mutation, as assess pyrosequencing 
(figure 1, panel D). No mutation on HER2, PI3KCA, BRAF or KRAS genes or rearrangement 
of ALK gene was found. Consequently, a re-challenge with erlotinib resulted in a 5 month 
stable disease. The patient died from respiratory failure because of multiple pulmonary 
metastasis, more than four years after initial diagnosis (figure 1, panel E). 
Page 7 of 17
A
cc
ep
te
d 
M
an
us
cr
ip
t
Discussion 
We report two LFS patients diagnosed with EGFR-mutated lung adenocarcinoma. 
Observational studies show that lung cancer belong to the spectrum of predisposed tumors in 
LFS [4]. According to Chompret criteria revised in 2009, a proband diagnosed with lung 
cancer before the age of 46 years and with at least one first-degree or second-degree relative 
with a core LFS tumor should be selected for a TP53 germline mutation testing. Our two 
patients do not meet these criteria and LFS was evocated because early-onset cancers in 
family history. Approximately 29%–35% of families with these criteria were shown to have 
TP53 germline mutations [6][7]. Importantly, recognition of LFS impacts the familial and 
personal cancer risk assessment, regarding potential radio-induced neoplasms. Thoracic 
oncologists should be aware of the possibility of this inherited predisposition syndrome 
especially when familial history of early-onset cancers is known. Our cases highlight the need 
for exhaustive medical family history interrogation when lung cancer is diagnosed, notably 
for young and non-smoker patients. 
The literature is scarce regarding epidemiologic characteristics of lung cancer in LFS. The 
International Agency for R search on Cancer mutation database collecting the germline TP53
mutation reports various pathological subtypes in this restricted population [8]. 
Adenocarcinomas, including lepidic growth carcinomas (previously known as 
bronchoalveolar), represent the largest part of the confirmed pathological type when TP53
germline mutation is known (figure 2, panel A). In addition, majority of these tumors arise 
before the fifth decade and for a large part in women (figure 2, panel B). To date, this 
database do not contain molecular characteristic of these tumors. In our two patients, EGFR
mutational status was unknown at diagnosis, but found during follow-up. Interestingly, co-
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occurrence of tumoral somatic TP53 mutations and EGFR mutations has been found in 34% 
of lung adenocarcinomas in a recent international project [9]. Two retrospective studies tried 
specifically to assess this association, based on mixed genomic and immunohistochemical 
approaches [5][10]. Tumoral p53/arf pathway inactivation was observed in respectively 100% 
and 58.1% of EGFR-mutated lung cancers, supporting this hypothesis. Interestingly, a similar 
distribution of germinal and tumoral mutations is observed in the TP35 gene coding sequence, 
occurring preferentially in the DNA binding domain (exon 5 to 8). Nevertheless, it appears 
that all tumoral TP53 mutations are not equivalent regarding their intrinsic prognostic value. 
Indeed, a recent publication has described that non-disruptive TP53 mutations are associated 
with a worse outcome in EGFR-mutated NSCLC [11]. Moreover, a recent analysis of age of 
cancer onset from the IARC database suggests unequal repercussion of the different TP53
germline missense mutations [12]. Taken together, these clinical data suggest an important 
heterogeneity concerning the tumorigenic potential of the different subtype of TP53
mutations. 
No exhaustive data concerning molecular biologic characteristics of lung cancers in the 
context of LFS has been published so far. Nevertheless, a growing number of publications 
reported EGFR mutant lung cancer in carriers of LFS suggesting a potential link between 
these two conditions [13][14][15][16]. Table 1 recapitulates important characteristics of the 
previous cases reported as well as our two patients. Consistent with IARC database, the 
majorities of tumors arise before the fifth decade and occur predominantly in woman. 
Interestingly, a majority of LFS patients harboring EGFR and/or ERBB2 mutated lung 
adenocarcinomas encompass good tumoral and clinical response to targeted therapy (except 
for the patient with T790M resistance mutation). The benefit appears to be quite similar than 
in non-LFS population with a progression-free survival of approximately one year. Some 
dedicated studies are needed to confirm this observation. As expected from clinical trials, 
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rechallenge with EGFR-TKI after progression show no benefit in our second case, even in the 
absence of identified resistance mutation. Third generation TKI recently show promising anti-
tumor activity, but current investigation are limited to the tumors with identified resistance 
mutation. Furthermore, we report for the first time acquisition of EGFR-TKI resistance 
mutation in the context of LFS. Familial cases of germline T790M may exist in 50% of these 
cases [17].It was ruled out in our first patient because allele frequency was not consistent with 
this hypothesis (around 7%) and the mutation was not found in her daughter genome (data not 
shown). However, we cannot exclude that EGFR T790M mutation was not present at the time 
of diagnosis because reduced sample materials from hepatic needle-biopsy do not allow us to 
perform molecular biology. Still, these cases suggest a common natural history of resistance 
to TKI than in general population. In LFS patients, as the first genetic hit is inherited, we 
argue that a second-hit, according Knudson hypothesis, can arise sooner in the time course of 
tumorigenesis. Interestingly, some authors incriminate radiation therapy or chemotherapy as a 
second hit. Notably, five of six LFS cases with EGFR-mutated lung adenocarcinoma were 
previously treated with chemotherapy or radiotherapy in a context of mammary malignancies. 
Even if a causative role remains to be demonstrated, benefice-risk assessment of radiotherapy 
should be carefully evaluated and discussed with patients in this particular setting. 
In conclusion, thoracic oncologists should evoke LFS in the context of illegitimate lung 
cancer (young and non-smoker patients). EGFR mutation is frequently reported in the Li-
Fraumeni setting, but epidemiological studies are needed to assess this potential association. 
Response to targeted therapy seems to be similar as in the general population. Arguably, we 
show for the first time that same resistance mechanism could arise in the LFS context.. 
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Legends:
Figure 1:
(A) EGFR exon 19 deletion diagnosed by automated electrophoresis system (LabChip GX, 
Perkin Elmer®). (B) EGFR T790M resistance mutation (ACG?ATG) as assessed by 
pyrosequencing of tumoral DNA. (D) EGFR L858R activating mutation (CTG?CGG)  as 
assessed by pyrosequencing of tumoral DNA (*: indicate mutated nucleotide or deleted 
allele). (C, E) Evolution of the sum of the longest diameters for all targeted lesions based on 
CT-scan measurement during follow-up.  
Figure 2:
(A) Pie chart of pathological types of lung neoplasm in germline TP53 mutation carriers 
(n=34) (†: including the bronchioloalveolar carcinoma). (B) Diagram of age and sex 
repartition of lung cancer in LFS patients (n=33; age missing for one patient). Data extracted 
from the International Agency for Research on Cancer p53 mutation database [9].
Table 1:
Clinical and biological characteristics of LFS patients diagnosed with EGFR-mutated lung 
adenocarcinoma. Obtained from case reports published in the literature. (CR: complete 
response, PR: partial response, PD: progressive disease) 
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